Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR

Journal of Cellular Physiology

Volumn 227, Issue 1, 2012, Pages 204-212

  Berg, Daniela ^a   Wolff, Claudia ^a   Malinowsky, Katharina ^a   Tran, Kai ^a   Walch, Axel ^b   Bronger, Holger ^a   Schuster, Tibor ^c   Höfler, Heinz ^a   Becker, Karl Friedrich ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN RECEPTOR ALPHA; FORMALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE; PARAFFIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; STAT3 PROTEIN; TRANSCRIPTION FACTOR SNAIL; UROKINASE RECEPTOR; UVOMORULIN;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CELL ADHESION; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR INTERACTION; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TISSUE CHARACTERIZATION; UPREGULATION;

BREAST NEOPLASMS; CLUSTER ANALYSIS; FEMALE; FORMALDEHYDE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PARAFFIN EMBEDDING; PROTEIN ARRAY ANALYSIS; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 80054952604     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22718     Document Type: Article

References (37)

1. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. 1997. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72:1-22.
2. Becker KF, Schott C, Hipp S, Metzger V, Porschewski P, Beck R, Nahrig J, Becker I, Höfler H. 2007. Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J Pathol 211:370-378.
3. Berg D, Hipp S, Malinowsky K, Böllner C, Becker KF. 2010. Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissues. Eur J Cancer 46:47-55.
4. Blasi F, Carmeliet P. 2002. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 38:932-943.
5. Cicenas J, Urban P, Kung W, Vuaroqueaux V, Labuhn M, Wight E, Eppenberger U, Eppenberger-Castori S. 2006. Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur J Cancer 42:636-645.
6. Dancey J, Sausville EA. 2003. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2:296-313.
7. Eisen MB, Spellman PT, Brown PO, Botstein D. 1998. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95:14863-14868.
8. Emens LA. 2005. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther 12:243-253.
9. Espina V, Mehta AI, Winters ME, Calvert V, Wulfkuhle J, Petricoin EF 3rd, Liotta LA. 2003. Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 3:2091-2100.
10. Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE. 2009. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor positive tumors. Breast Cancer Res 11:R11.
11. Grubb RL, Deng J, Pinto PA, Mohler JL, Chinnaiyan A, Rubin M, Linehan WM, Liotta LA, Petricoin EF, Wulfkuhle J. 2009. Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. J Proteome Res 8:3044-3054.
12. Hemsen A, Riethdorf L, Brunner N, Berger J, Ebel S, Thomssen C, Janicke F, Pantel K. 2003. Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells. Int J Cancer 107:903-909.
13. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, R. Seger R, Hynes NE, Yarden Y. 1996. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15:254-264.
14. Li C, Cao S, Liu Z, Ye X, Chen L, Meng S. 2010. RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells. Int J Cancer 127:1507-1516.
15. Liotta LA, Espina V, Mehta AI, Calvert V, Rosenblatt K, Geho D, Munson PJ, Young L, Wulfkuhle J, Petricoin EF. 2003. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 3:317-325.
16. Mabrouk RA, Ali-Labib R. 2003. Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma. Clin Biochem 36:537-543.
17. Malinowsky K, Wolff C, Ergin B, Berg D, Becker KF. 2010. Deciphering signaling pathways in clinical tissues for personalized medicine using protein microarrays. J Cell Physiol 225:364-370.
18. Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, Frenkel E, Euhus D, Leitch M, Osborne C, Clifford E, Perkins S, Beitsch P, Khan A, Morrison L, Herlyn D, Terstappen LW, Lane N, Wang J, Uhr J. 2006. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 103:17361-17365.
19. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin IE, Liotta LA. 2001. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20:1981-1989.
20. Piccart M, Lohrisch C, Di Leo A, Larsimont D. 2001. The predictive value of HER2 in breast cancer. Oncology 61:73-82.
21. Pierga JY, Bonneton C, Magdelenat H, Vincent-Salomon A, Nos C, Boudou E, Pouillart P, Thiery JP, de Cremoux P. 2005. Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. Int J Cancer 114:291-298.
22. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y. 1996. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452-2467.
23. Ploug M, Ellis V. 1994. Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett 349:163-168.
24. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K. 1991. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 266:1926-1933.
25. Remmele W, Stegner E. 1987. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138-140.
26. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Menard S, Pierotti MA, Testori A. 1991. Prognostic significance of HER2-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49:44-49.
27. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Janicke F, Graeff H. 1997. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78:285-296.
28. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF 3rd, Wulfkuhle JD. 2005. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteom 4:346-355.
29. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182.
30. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712.
31. Tan M, Li P, Sun M, Yin G, Yu D. 2006. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene 25:3286-3295.
32. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Watanabe S, Hirota T, Tsugane S, Watanabe S, Tereda M, Ymamoto H. 1990. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. Cancer 65:1794-1800.
33. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. 2007. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145.
34. Wolff C, Malinowsky K, Berg D, Schragner K, Schuster T, Walch A, Bronger H, Höfler H, Becker KF. 2010. Signalling networks associated with urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in breast cancer tissues: new insights from protein microarray analysis. J Pathol 223:54-63.
35. Wulfkuhle J, Pierobon M, Laird J, Espina V, Liotta IL, Eserman L, Petricoin E. 2009. Discovery of a new phospho-HER2+/FISH- molecular subtype of human breast cancer by functional pathway mapping. J Clin Oncol ASCO Annual Meeting 27.
36. Wulfkuhle JD, Edmiston KH, Liotta LA, Petricoin EF 3rd. 2006. Technology insight: pharmacoproteomics for cancer-promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol 3:256-268.
37. Yarden Y, Sliwkowski MX. 2001. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137.